Rankings
▼
Calendar
ESPR FY 2020 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ESPR
Esperion Therapeutics, Inc.
$519M
FY 2020 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$228M
+53.4% YoY
Gross Profit
$225M
98.9% margin
Operating Income
-$121M
-53.3% margin
Net Income
-$144M
-63.1% margin
EPS (Diluted)
$-6.05
Cash Flow
Operating Cash Flow
-$85M
Free Cash Flow
-$99M
Stock-Based Comp.
$28M
Balance Sheet
Total Assets
$353M
Total Liabilities
$449M
Stockholders' Equity
-$96M
Cash & Equivalents
$305M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$228M
$148M
+53.4%
Gross Profit
$225M
$148M
+51.8%
Operating Income
-$121M
-$93M
-30.4%
Net Income
-$144M
-$97M
-47.7%
← Q4 2019
All Quarters
Q1 2020 →